Investor Relations - MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.

SEC Filings

Form	Description	Filing date	View
10-K	Annual report which provides a comprehensive overview of the company for the past year	Mar 18, 2022	View HTML 0001564590-22-011026.pdf 0001564590-22-011026.rtf 0001564590-22-011026.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K	Annual report which provides a comprehensive overview of the company for the past year	Mar 24, 2023	View HTML 0000950170-23-009762.pdf 0000950170-23-009762.rtf 0000950170-23-009762.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K	Annual report which provides a comprehensive overview of the company for the past year	Mar 21, 2024	View HTML 0000950170-24-034672.pdf 0000950170-24-034672.rtf 0000950170-24-034672.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q	Quarterly report which provides a continuing view of a company's financial position	Nov 29, 2021	View HTML 0001564590-21-058700.pdf 0001564590-21-058700.rtf 0001564590-21-058700.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Data provided by Kaleidoscope.